The catastrophic out-of-pocket health expenditure of multiple sclerosis patients in Iran.
Catastrophic health expenditure
Multiple sclerosis
Out-of-pocket payment
Poverty caused by disease
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
20 Mar 2021
20 Mar 2021
Historique:
received:
23
08
2020
accepted:
08
03
2021
entrez:
21
3
2021
pubmed:
22
3
2021
medline:
15
5
2021
Statut:
epublish
Résumé
The present study was designed and conducted to evaluate multiple sclerosis (MS) treatment costs and the resulting economic impact imposed on MS patients in Iran. This was a cross-sectional study, among randomly selected 300 MS patients, registered in the MS Association of East Azerbaijan Province, Iran (1 year after their treatment began). The regression analysis, ANOVA, T-test, and chi-square were used. The average amount of out-of-pocket payments (OOPs) by MS patients during the previous year was 1669.20 USD, most of which was spent on medication, rehabilitation care, and physician visits. Their mean annual income was 5182.84 USD. Fifty four percent of families with an MS patient suffer from catastrophic health expenditure (CHE) and 44% experience poverty caused by the OOPs. Occupational status, having supplemental health insurance, and being residents of Tabriz significantly affect OOPs, CHE, and the resulting poverty (P < 0.05). The catastrophic financial burden of health care costs on MS patients and their families justifies health policymakers to promote pre-payment systems and provide subsidies to less well-off patients to protect them from the unfairness of OOPs and its resulting CHE and poverty.
Sections du résumé
BACKGROUND
BACKGROUND
The present study was designed and conducted to evaluate multiple sclerosis (MS) treatment costs and the resulting economic impact imposed on MS patients in Iran.
METHODS
METHODS
This was a cross-sectional study, among randomly selected 300 MS patients, registered in the MS Association of East Azerbaijan Province, Iran (1 year after their treatment began). The regression analysis, ANOVA, T-test, and chi-square were used.
RESULTS
RESULTS
The average amount of out-of-pocket payments (OOPs) by MS patients during the previous year was 1669.20 USD, most of which was spent on medication, rehabilitation care, and physician visits. Their mean annual income was 5182.84 USD. Fifty four percent of families with an MS patient suffer from catastrophic health expenditure (CHE) and 44% experience poverty caused by the OOPs. Occupational status, having supplemental health insurance, and being residents of Tabriz significantly affect OOPs, CHE, and the resulting poverty (P < 0.05).
CONCLUSION
CONCLUSIONS
The catastrophic financial burden of health care costs on MS patients and their families justifies health policymakers to promote pre-payment systems and provide subsidies to less well-off patients to protect them from the unfairness of OOPs and its resulting CHE and poverty.
Identifiants
pubmed: 33743679
doi: 10.1186/s12913-021-06251-4
pii: 10.1186/s12913-021-06251-4
pmc: PMC7981983
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
257Références
Int J Rehabil Res. 1986;9(2):155-65
pubmed: 3771036
Int J Equity Health. 2015 Jan 20;14:8
pubmed: 25599715
J Neurol. 2002 Feb;249(2):152-63
pubmed: 11985380
Mult Scler. 2007 May;13(4):547-58
pubmed: 17463077
Mult Scler. 1998 Oct;4(5):419-25
pubmed: 9839302
Mult Scler. 2007 Jul;13(6):800-4
pubmed: 17613609
Arch Neurol. 1982 Apr;39(4):256
pubmed: 7073539
Ann Neurol. 1994 Dec;36 Suppl 2:S218-30
pubmed: 7998791
Health Policy. 2007 Oct;83(2-3):304-13
pubmed: 17379351
Neurol Sci. 2001 Aug;22(4):307-15
pubmed: 11808854
Iran J Public Health. 2011;40(1):94-9
pubmed: 23113061
J Occup Rehabil. 2005 Mar;15(1):69-84
pubmed: 15794498
Lancet Neurol. 2005 Sep;4(9):556-66
pubmed: 16109362
Arch Phys Med Rehabil. 2004 Feb;85(2):201-9
pubmed: 14966703
Int J Equity Health. 2015 May 14;14:46
pubmed: 25971679
Expert Rev Pharmacoecon Outcomes Res. 2010 Aug;10(4):433-40
pubmed: 20482233
Health Policy. 2010 Jan;94(1):26-33
pubmed: 19735960
Glob J Health Sci. 2016 Jan 21;8(9):53778
pubmed: 27157166
Med J Islam Repub Iran. 2017 Aug 02;31:43
pubmed: 29445672
PLoS One. 2019 Jan 23;14(1):e0208837
pubmed: 30673707
Mult Scler. 2012 May;18(5):647-53
pubmed: 22183935
Int J Health Policy Manag. 2014 Sep 17;3(5):243-9
pubmed: 25337598
Eur J Health Econ. 2006 Sep;7 Suppl 2:S5-13
pubmed: 17310344
Eur J Health Econ. 2012 Feb;13(1):81-91
pubmed: 21080024
PLoS One. 2013 Jul 04;8(7):e67812
pubmed: 23861812
Expert Rev Pharmacoecon Outcomes Res. 2006 Apr;6(2):145-54
pubmed: 20528550
BMC Neurol. 2020 May 23;20(1):205
pubmed: 32446303
Arch Iran Med. 2014 Jul;17(7):507-13
pubmed: 24979565
Mult Scler. 2000 Apr;6(2):91-8
pubmed: 10773854
Bull World Health Organ. 2009 Mar;87(3):238-44, 244A-244D
pubmed: 19377721